Navigation Links
Allscripts announces first quarter 2013 results
Date:5/9/2013

nses and transaction-related costs of approximately $18.3 million and $3.0 million for the three months ended March 31, 2013 and 2012, respectively, comprised of the following: 

Three Months EndedThree Months Ended3/31/133/31/12Severance and other costs$12.6$0.0MyWay product consolidation3.70.0Transaction-related costs2.01.5Other0.01.5$18.3$3.0 Table 5Allscripts Healthcare Solutions, Inc.Non-GAAP Financial Information - Adjusted EBITDA(In millions)(Unaudited)Three Months EndedThree Months Ended3/31/133/31/12Total revenue, as reported

$347.1$364.7Acquisition related deferred revenue adjustment

0.90.8Total non-GAAP revenue$348.0$365.5Net income/(loss), as reported

($11.6)$5.8Tax provision/(benefit)

(13.2)3.7Interest expense (income) and other (income) expense (a)

3.22.0Stock-based compensation expense

8.07.7Depreciation and amortization

40.835.2Acquisition-related deferred revenue adjustments

0.90.8Acquisition-related amortization

1.20.0Non-recurring expenses and transaction-related costs (b)

20.43.0Non-GAAP adjusted EBITDA$49.8$58.3Non-GAAP adjusted EBITDA margin

14%16%(a) Interest expense (income) and other (income) expense has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization. Additionally, the amount presented for the three months ended March 31, 2013 excludes gains on investments totaling $8.0 million. (b)  Depreciation expense totaling $0.4 million has been excluded from non-recurring expenses for the three months ended March 31, 2013 since this amount is also included in depreciation and amortization.  Table 6Allscripts Healthcare Solutions, Inc.Supplemental Data Sheet(In millions)(unaudited)Pct ChangeCY 2012
'/>"/>

SOURCE Allscripts Healthcare Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Allscripts Adds Two Independent Directors to Board
2. Developers: Deadline Approaching for Allscripts Million Hearts CDS Challenge
3. Allscripts Announces Second Quarter 2012 Results
4. Allscripts and Aprima Settle Legal Matters
5. Allscripts Announces Third Quarter 2012 Results
6. Baylor University Medical Center activates Allscripts electronic health record system
7. Allscripts adopts majority voting policy for directors
8. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
9. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. Misonix Announces New Distribution Agreement For Panama
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015   Synthetic Biologics, Inc. ... on protecting the microbiome, as well as treating other ... appointed Chief Financial Officer, Treasurer and Secretary effective June ... who will be leaving the Company in May to ... Synthetic Biologics operational, financial and international biotech industry experience, ...
(Date:5/4/2015)... BOULDER, Colo., May 4, 2015  Array BioPharma ... for the third quarter of its fiscal year ... Chief Executive Officer of Array, noted, "With the close ... binimetinib and encorafenib, two innovative oncology products in ... each product in 2016. These transformative transactions have ...
(Date:5/4/2015)... , May 4, 2015 ... has granted an Orphan Drug Designation (ODD) for rimeporide, ... dystrophy (DMD). DMD is a rare, life-threatening disease affecting ... muscle loss. It is the most common and serious ... a selective sodium/proton exchanger type-1 inhibitor, originally developed by ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2
(Date:5/4/2015)... In response to the proposed mammography ... (USPSTF), Strategic Radiology® (SR®) fully aligns itself with ... Gynecologists (ACOG), the American College Of Surgeons, Susan ... (ACS), American College of Radiology (ACR), and Society ... screening mammography for women beginning at age 40 ...
(Date:5/4/2015)... For partners who’d like to become parents, Astroglide ... TTC™ (Trying to Conceive) . Unlike traditional lubricants that ... TTC™ is specially formulated to provide a better environment ... Disease Control, an average of one in eight ... pregnancy, and over 7.4 million women have ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... 2015 “St. Louis has long represented ... the West,” so it is the perfect place for ... Dr. Ben Litalien, Chief Development Officer for Zerorez. ... and will provide veterans with a $10,000 discount on ... to have a number of Military Veterans in its ...
(Date:5/3/2015)... 03, 2015 AvePoint, ... platforms and devices, today announced it is a ... Professionals (IAPP) Asia Privacy Forum, taking place May ... the event, AvePoint will showcase its compliance, risk, ... platforms. , Visit AvePoint for New Solutions ...
Breaking Medicine News(10 mins):Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4
... hernias are one of the most common conditions treated ... annually. Although ventral hernia repair (VHR) is a common ... infection has been identified as a consistent risk factor ... which appears in the November issue of The ...
... such as Viagra use is linked to development of vision ... disorders have used Viagra medicines. It is found that it ... cause risk of blindness. Men most at risk for the ... heart disease, high blood pressure and high cholesterol, among other ...
... Findings presented at the American Society of Therapeutic Radiation ... antigen (PSA) // significantly reduces the mortality associated with ... most prevalent type of cancer found in men after ... in the male reproductive system, which produces some of ...
... is essential for the lipid and carbohydrate metabolism, and ... to insulin.// The use of glucose by the peripheral ... has potential impact on long-term complications. ,In ... and an association between the proper metabolic control and ...
... and colleagues have identified a candidate gene, Sipa1, ... in cancer. Cancer mortality is most often the ... studies from Kent Hunter’s group demonstrated that the ... efficiency. They expressed the polyoma middle-T transgene in ...
... in women after menopause has been found to enhance ... cholesterol (the “good” cholesterol) in women, according to a ... and is characterized by decreased levels of the female ... the vagina and uterus. In addition the hormone ...
Cached Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Impotence drug such as Viagra may cause Vision Loss 2Health News:Carnitine deficiency in children and adolescents with type 1 diabetes 2Health News:Researchers Identify Sipa 1 Gene, Responsible For Cancer Metastasis 2Health News:Testosterone Therapy can improve sexual function in postmenopausal women 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: